Introduction
Refractory anemia (RA) is a clonal myelodysplastic syndrome (MDS) characterized by dysplastic erythropoiesis and less than 5% bone marrow (BM) blasts [1] . Although BM fibrosis can be seen in about 10-15% MDS patients and is a poor prognostic indicator, it is found more commonly in higher-risk cases and therefore only occasionally in RA [2] [3] [4] [5] [6] [7] . Accordingly, recognizing that most cases of BM fibrosis occur in refractory anemia with excess (5-19%) blasts (RAEB) MDS, the current World Health Organization (WHO) Classification includes the provisional entry, RAEB with fibrosis (RAEB-F). The working definition of RAEB-F includes diffuse coarse reticulin fibrosis, with or without collagen fibrosis. Since BM aspirates are often difficult to obtain from a fibrotic marrow, the presence of excess blasts is usually facilitated by BM biopsy immunohistochemistry (CD34 in particular). Moreover, increased numbers of dysplastic megakaryocytes may be seen [1] .
Herein, we present a rare case of an RA patient whose BM picture evolved with fibrosis, yet sufficiently to satisfy WHO diagnostic criteria for the distinctive myeloproliferative neoplasm (MPN), primary myelofibrosis (PMF) [1] . Specifically, this evolution was characterized by the emergence of a JAK2-mutant clone, splenomegaly, extramedullary hematopoiesis, and the loss of MDS-associated ring sideroblasts (RS) and a characteristic 20q chromosomal deletion. To the best of our knowledge, this is the first documented case report of JAK2 V617F PMF emerging from RA, providing insight into the process of clonal evolution.
Case report
A 64-year-old man presented for consultation, with a 3-year history of anemia. He had a remote history of smoking and a brother with MDS that transformed to acute myeloid leukemia (AML). Physical exam was remarkable for the absence of lymphadenopathy or hepatosplenomegaly. Complete blood counts revealed hematocrit 31.4%, MCV 105 fl, WBC 3.3×10 9 /L, and platelets 118×10 9 /L. Six months prior to consultation, peripheral blood and BM studies revealed non-specific dysplastic features that did not meet MDS thresholds. BM examination was repeated at consultation and was diagnostic for RA ( Fig. 1) . Specifically, the aspirate showed >10% dysplastic erythroid forms (i.e., with irregular nuclear contours and megaloblastoid forms), a slightly decreased M/E ratio (1.8:1), full granulocytic maturation with eosinophilia (9%), and insufficient numbers of megakaryocytes for evaluation. Iron stores were decreased and there were 9% RS. The biopsy was mildly hypercellular (50%), with areas of abnormally localized immature precursors and a few mononuclear megakaryocytes. Flow cytometry revealed <1% blasts. Cytogenetics revealed 2 normal metaphases and 19 with concurrent loss of the Y chromosome and deletion 20q13.1. Retrospective molecular testing was negative for JAK2
V617F
. No specific treatment was recommended.
The patient's counts remained fairly stable without interventions for almost 3 years. He then developed a respiratory illness, was found to have a hematocrit of 22%, and received 2 U of packed red cells. Repeat BM examination showed hypercellularity (85%), M/E ratio of 1:1 with decreased myelopoiesis, increased megakaryocytes (small hypolobated and large polylobated forms) ( /L), the patient was managed with growth factor support: erythropoietin (Epo) and granulocyte colony-stimulating factor.
Therapy was subsequently altered to include thalidomide and prednisone. Over the subsequent 2 years, the patient developed significant splenomegaly (up to 18 cm on ultrasonic examination) and progressive anemia. Repeat BM examination indicated progression of the marrow fibrosis but no increase in immature cells. Specifically, cellularity was now 95%, with increased and left-shifted erythropoiesis (with no RS seen), decreased myelopoiesis with normal maturation, increased and clustered megakaryocytes with atypia (large hyperlobated and small hypolobated forms). Reticulin deposition was increased (3+), and trichrome demonstrated slight collagen deposition. CD34 and CD117 immunostains revealed less than 5% blasts. The JAK2 V617F mutation was detected. Potentially consistent with progression from an ancestral clone, the 20q deletion was no longer detectable by conventional cytogenetics. Instead, one metaphase was normal and 19/20 showed 45, X, -Y.
Three months following that BM examination, splenectomy revealed a 578-g specimen with extramedullary hematopoiesis, numerous megakaryocytes with "cloud-like" thickly connected nuclear lobes (Fig. 3a) , marked (3+) reticulin fibrosis (Fig. 3b) , and no excess blasts (<1%), consistent with the concurrent JAK2 mutation-positive myelofibrosis BM diagnosis. Postoperative course was complicated by multi-organ failure, sepsis, Clostridium difficile colitis, aspiration pneumonia/respiratory failure with anoxic brain injury, requiring prolonged hospitalizations and transfers to and from a skilled nursing facility.
Repeat BM studies 5 months later revealed hypercellularity, with interval loss of megakaryocyte hyperplasia, and increased blasts (7% in the aspirate). The karyotype revealed 3 normal metaphases and 17/20 with loss of Y. However, JAK2 V617F was no longer detectable. No additional treatment was provided except for supportive care. The patient expired approximately 6 years after the original diagnosis.
Discussion

BM fibrosis has long been associated with MDS [2-5].
More recent studies have clarified that significant fibrosis (grades 2-3) which occurs in 10-15% of MDS patients, is associated with advanced disease and poor prognosis [6, 7] . However, in our case, the appearance of fibrosis coincided with the loss of MDS-associated RS and del(20q). Furthermore, there have been descriptions of MDS patients transitioning to acute panmyelosis with myelofibrosis (APMF) [8] [9] [10] . However, APMF is characterized by an abrupt onset with fever and bone pain, with no to minimal splenomegaly, more numerous megakaryocytes and leukemic level (≥20%) blasts [1] . These features were lacking in our case.
A further differential consideration is whether the initial dysplasia was simply part of the PMF clone. Although some degree of dysplasia (particularly megakaryocytic) can be seen in PMF, dysplasia is not to the extent of MDS and may require subtle flow cytometric analysis to discern [1, 11, 12] . Again, the transition to PMF in this case was Another differential diagnostic consideration included an unclassifiable (U), overlapping disorder: MDS/MPN-U. In particular, given the previous documentation of 9% RS and the emergence of JAK2 V617F , the provisional MDS/MPN-U entity RA with RS associated with marked thrombocytosis (RARS-T) was considered [1] . However, our patient never had a thrombocytosis (platelet count ≥450×10 9 /L), RS were less than the required 15% threshold, and RS were no longer detectable upon the myelofibrotic transition.
Thus, we propose this case represented a true example of PMF emerging from RA. Accordingly, there have been a few similar reports of "transitional" [13] MDS→PMF [10, [13] [14] [15] [16] [17] , although ours may be the first documented in the JAK2 molecular era. A model is presented in Fig. 4 , depicting the transition to JAK2 V617F -mutant PMF from antecedent JAK2 wt RA. Consistent with the existence of at least two serially distinct but related clones, both disorders were characterized by loss of the Y chromosome, yet RA was marked by 9% RS and del(20q), and PMF showed neither. Arguing for a third clonogenic intermediary, blastic progression of PMF ultimately resulted with loss of JAK2 V617F allele, as has been reported during the transformation of BCR-ABL1-negative MPNs [18, 19] .
A final curious component to this case (leftmost aspect of Fig. 4) , is that the sibling of our patient also acquired MDS that transformed to AML. Familial occurrence of MDS and/ or AML is rare, tends to occur at younger presentation, and in families with more than one affected first-degree relative. It is associated with BM failure syndromes, in families with familial monosomy 7 [20] , inherited telomere abnormalities [21] , mutations of CEBPA [22, 23] , or in familial platelet disorder with propensity to develop myeloid malignancy (FPD/AML) in which germline RUNX1 mutations have been implicated [22, [24] [25] [26] . Moreover, although not yet associated with familial MDS/AML, mutations in TET2 and ASXL1 are common in MDS/MPN [27, 28] , and germline TET2 variants have been described in myeloid malignancy [29] . Whether the similar disorders in these siblings arose due to common predisposing genetic and/or environmental factors remains to be determined.
